Based on the key indicators related to Sarepta Therapeutics' liquidity, profitability, solvency, and operating efficiency, Sarepta Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in April. At this time, Sarepta Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 253.1 M in 2025, whereas Short Term Investments are likely to drop slightly above 214.4 M in 2025. Key indicators impacting Sarepta Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Sarepta Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Sarepta Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Sarepta Therapeutics.
Please note, the imprecision that can be found in Sarepta Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sarepta Therapeutics. Check Sarepta Therapeutics' Beneish M Score to see the likelihood of Sarepta Therapeutics' management manipulating its earnings.
Sarepta Therapeutics Stock Summary
Sarepta Therapeutics competes with Krystal Biotech, PTC Therapeutics, Iovance Biotherapeutics, Madrigal Pharmaceuticals, and Viking Therapeutics. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Sarepta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 840 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Sarepta Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Sarepta Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Sarepta Therapeutics's current stock value. Our valuation model uses many indicators to compare Sarepta Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sarepta Therapeutics competition to find correlations between indicators driving Sarepta Therapeutics's intrinsic value. More Info.
Sarepta Therapeutics is currently regarded as top stock in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.19 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sarepta Therapeutics is roughly 5.23 . At this time, Sarepta Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sarepta Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Sarepta Therapeutics Systematic Risk
Sarepta Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sarepta Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Sarepta Therapeutics correlated with the market. If Beta is less than 0 Sarepta Therapeutics generally moves in the opposite direction as compared to the market. If Sarepta Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sarepta Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sarepta Therapeutics is generally in the same direction as the market. If Beta > 1 Sarepta Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Sarepta Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sarepta Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Sarepta Therapeutics growth as a starting point in their analysis.
Sarepta Therapeutics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sarepta Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sarepta Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sarepta Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Sarepta Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sarepta Therapeutics's daily price indicators and compare them against related drivers.
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.